首页> 外文期刊>Vaccine >Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2.
【24h】

Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2.

机译:重组猪细小病毒样颗粒作为抗原载体的开发,该颗粒是由携带猪圆环病毒2型免疫反应性表位的杂合VP2蛋白形成的。

获取原文
获取原文并翻译 | 示例
           

摘要

Virus-like particles (VLPs) are non-replicative vectors for delivery of heterologous epitopes and induction of immune responses. In this study, a self-assembled porcine parvovirus (PPV) VP2 capsid protein [PPV:VLP-(PCV2)] carrying immunoreactive epitopes, residues 165-200 from the Porcine circovirus 2 (PCV2) virus nucleoprotein was constructed. Immunogenicity study was carried out with hybrid VLPs derived from HEK-293 cells infected with recombinant adenovirus vectors. To our knowledge, this study presents the first demonstration that hybrid non-replicative PPV VLPs carrying PCV2 immunoreactive epitopes can induce stronger antibody responses against PCV2 than recombinant adenovirus of PCV2 ORF2, in the absence of any adjuvant. The hybrid VLPs [PPV:VLP-(PCV2)] might be a promising candidate vaccine for better prevention of the diseases associated with PCV2 as well as with co-infection by PCV2 and PPV.
机译:病毒样颗粒(VLP)是用于递送异源表位和诱导免疫反应的非复制性载体。在这项研究中,构建了带有免疫反应性表位的自组装猪细小病毒(PPV)VP2衣壳蛋白[PPV:VLP-(PCV2)],来自猪圆环病毒2(PCV2)病毒核蛋白的残基165-200。使用衍生自重组腺病毒载体感染的HEK-293细胞的杂交VLP进行免疫原性研究。据我们所知,这项研究提出了第一个证明,即在没有任何佐剂的情况下,携带PCV2免疫反应性表位的杂交非复制PPV VLP可以比PCV2 ORF2重组腺病毒诱导更强的针对PCV2的抗体反应。混合VLP [PPV:VLP-(PCV2)]可能是一种有前途的候选疫苗,可以更好地预防与PCV2相关的疾病以及与PCV2和PPV的共同感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号